Seeking Alpha

Alkermes (ALKS +5%) discusses three new drug candidates at its R&D day: An MS prodrug...

Alkermes (ALKS +5%) discusses three new drug candidates at its R&D day: An MS prodrug program, a treatment for pain, and a cancer immunotherapy candidate. The company also announces the initiation of a Phase II study for the schizophrenia treatment ALKS 3831.
Comments (1)
  • bil4Bill
    , contributor
    Comments (21) | Send Message
     
    alks has a great future.
    17 Jul 2013, 03:58 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector